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Abstract
The suitability of IgM antibodies to PGL-1 for monitoring the response to multidrug therapy (MDT) was sequentially tested by 
ELISA in 105 leprosy patients, and bacterial indexes (BI) were also determined. Patients were divided into 3 groups: group 1, 
34 multibacillary (MB) patients treated for 12 months with MDT-MB; group 2, 33 MB patients treated for 24 months with MDT-
MB, and group 3, 38 paucibacillary (PB) patients treated for 6 months with MDT-PB. Untreated MB patients exhibited higher 
antibody levels (mean ± SEM): group 1 (6.95 ± 1.35) and group 2 (12.53 ± 2.02) than untreated PB patients (1.28 ± 0.35). 
There was a significant difference (P < 0.01) in anti-PGL-1 levels in group 1 patients: untreated (6.95 ± 1.35) and treated for 
12 months (2.78 ± 0.69) and in group 2 patients: untreated (12.53 ± 2.02) and treated for 24 months (2.62 ± 0.79). There was 
no significant difference between untreated (1.28 ± 0.35) and treated (0.62 ± 0.12) PB patients. Antibody levels correlated with 
BI. The correlation coefficient (Pearson’s r) was 0.72 before and 0.23 (P < 0.05) after treatment in group 1 and 0.67 before 
and 0.96 (P < 0.05) after treatment in group 2. BI was significantly reduced (P < 0.01) after 12 and 24 months on MDT (group 
1: 1.26-0.26; group 2: 1.66-0.36). Our data indicate that monitoring anti-PGL-1 levels during MDT may be a sensitive tool for 
evaluating treatment efficacy. These data also indicate that the control of leprosy infection can be obtained with 12 months of 
MDT in MB patients. 
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Leprosy is a chronic infectious disease caused by My-
cobacterium leprae characterized by a broad spectrum of 
clinical manifestations ranging from the relatively limited 
lesions of the tuberculoid form (T) to the disseminative 
and progressive involvement of peripheral nerves, skin 
and other tissues of the lepromatous form (L). These polar 
forms are associated with the immunological response of 
the host to the infectious agent (1). Antibody production 
varies with the disease spectrum as a consequence of the 
bacillary load. Tuberculoid patients display lower levels of 
antibody production (2). In lepromatous patients, there is 
a lack of specific cell immune response to M. leprae and 
an increase in the humoral response, which does not play 
any protective role in leprosy (3).
Testing for the presence of the species-specific antibody 
to the M. leprae phenolic glycolipid-I (PGL-1) has been 
suggested as a method to detect new leprosy cases and 
for an early diagnosis of subclinical infection, since these 
antibodies reflect an early sign of antigenic stimulation (3-6). 
Although most studies of the incidence of leprosy in people 
seropositive for anti-PGL-1 have failed to demonstrate 
an increased risk, some investigators have reported an 
increase in the rate of detection of leprosy in seropositive 
contacts compared to seronegative contacts (7,8). 
ELISA has been used to detect anti-PGL-1 antibod-
ies, mainly of the IgM class. Results from previous PGL-1 
studies have demonstrated that the technique is sensitive 
for multibacillary leprosy but detects only 30 to 60% of 
paucibacillary cases (4). There is a significant correlation 
between IgM antibodies to PGL-1 and the bacterial index 
(BI), indicating that anti-PGL-1 IgM levels reflect the total 
bacillary load of leprosy patients and, thus, might be useful 
for monitoring patient response to antileprosy chemotherapy 
(9,10). Serology could provide a method to monitor leprosy 
patients under treatment since the levels of anti-PGL-1 
antibodies decrease during the administration of specific 
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therapy (1). A serologic test for the diagnosis of subclini-
cal infection and therapeutic follow-up has been applied, 
despite the high specificity and controversies surrounding 
the correlation of high levels of anti-PGL-1 antibodies with 
active, previous or future disease (11,12).
Large numbers of new cases of leprosy have been 
detected in Brazil over the last years. Even though the 
coefficient of prevalence has decreased, about 30,590 
new untreated cases were detected in 2007 (13). These 
data suggest that the Public Health Services should find 
new methods or therapeutic regimens for the control of 
the disease. Beside this increased detection of new cases 
of leprosy, it should be pointed out that about 60-70% of 
these cases (18,354-21,413 patients) are lepromatous, thus 
maintaining transmission of the disease (13).
The Health Ministry has defined new therapeutic 
regimens for leprosy in Brazil. Multibacillary (MB) patients 
should take the multidrug therapy (MDT-MB) with rifampicin 
(600 mg/month), clofazimine (300 mg/month and 50 mg/
day) and dapsone (100 mg/day) for 12 months instead of 
24 months (14). However, this short-term regimen was 
considered to be unsafe by some physicians and profes-
sionals working with the leprosy control program, even 
though a preliminary study showed no difference in leprosy 
treatment outcomes between 12- and 24-month multidrug 
regimens (15). No treatment changes have been tried for 
paucibacillary (PB) patients, who continue to receive MDT-
PB with rifampicin (600 mg/month) and dapsone (100 mg/
day) for 6 months (14). 
In the present study, serum anti-PGL-1 IgM levels and 
the BI were measured sequentially in leprosy patients before 
and after treatment to evaluate the suitability of using the 
levels of IgM antibodies to PGL-1 to monitor the response 
to the classic (24 month) and short-term (12 month) MDT 
regimen.
Patients and Methods
Patients
One hundred and five leprosy patients were followed in 
the Division of Dermatology and National Leprosy Refer-
ence Center, University Hospital, Faculty of Medicine of 
Ribeirão Preto, University of São Paulo, Brazil. They were 
classified according to the spectrum of the disease as MB, 
all of whom with a positive BI, and PB, all of whom with a 
negative BI. 
The patients were divided into 3 groups: group 1, MB 
patients treated for 12 months with MDT (MDT-MB, short-
term regimen); group 2, MB patients treated for 24 months 
with MDT (MDT-MB, classic regimen), and group 3, PB 
patients treated with MDT-PB for 6 months. MB patients 
were treated with standard multidrug therapy, which included 
dapsone, rifampicin and clofazimine for 12 months or 24 
months. PB patients also received the standard multidrug 
therapy with dapsone and rifampicin for 6 months. 
Antibody determinations were performed on patients 
before and after MDT. Serum was collected by venipuncture, 
centrifuged and stored at -20°C until use. Also, the BI was 
calculated by counting the acid-fast bacilli in slit-skin smears 
taken from the earlobe, knee, elbow, and skin lesions and 
stained by the Ziehl-Neelsen method.
 
Enzyme-linked immunosorbent assay (ELISA) 
Ninety-six-well polystyrene plates were coated with 2 µg/
mL antigen (PGL-1) in sodium carbonate buffer, pH 9.6, and 
stored at 4°C overnight until use. Serum from each patient 
was diluted 1:100 in 15 mM Tris-Tween (20 mM Tris, 150 
mM NaCl and 0.1% Tween) buffer containing 5% sheep 
serum and 10 µL was added to each well and the plate 
was incubated for 1 h at 37°C in a humid chamber. After 
1 h, the samples were washed with 15 mM Tris-Tween buf-
fer and anti-human IgM β-galactosidase conjugate diluted 
1:600 in 15 mM Tris-Tween buffer containing 5% sheep 
serum was added. The plates were then incubated at 37°C 
for 1 h. A fluorigenic substrate (10 µL 4-methylumbelliferyl 
β-D-galactopyranoside) was then added to the samples 
and the material was incubated at 37°C for 30 min. The 
plate was read with a multiskan ELISA reader. Sera with 
an absorbance at 450 nm greater than 0.028 (the mean 
absorbance plus three standard deviations of 35 healthy 
Brazilian control subjects) were considered to be positive. 
Each serum was tested in duplicate. The difference between 
these duplicates was about 3 to 5%. All assays were carried 
out at the same time (16).
Measurement of the bacterial index
A reasonably quantitative sample of M. leprae from the 
skin was obtained from slit-skin smears for BI measurement. 
The sample was stained by the Ziehl-Neelsen method to 
determine the density of bacteria in the lesion (BI), based 
on the count of acid-fast bacilli according to a standard 
method for the determination of the number of bacilli/field 
after examining 25-100 fields, on a logarithmic scale rang-
ing from 0-6+ (17).
Statistical analysis
A mixed linear model (18) was used to compare PGL-1 
levels at the two time points (before and after treatment) 
in each group and the Wilcoxon test (19) was used to 
compare the BI at the same time points (before and after 
treatment).
Results
A total of 105 leprosy patients were divided into 3 
groups: group 1, 34 MB patients treated for 12 months with 
MDT-MB; group 2, 33 MB patients treated for 24 months 
with MDT-MB, and group 3, 38 PB patients treated with 
MDT-PB for 6 months. 
Anti-PGL-1 levels were determined before and after 
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treatment. Untreated MB patients exhibited higher antibody 
levels (mean ± SEM): group 1 (6.95 ± 1.35) and group 2 
(12.53 ± 2.02) than untreated PB patients (1.28 ± 0.35). 
Table 1 shows higher levels of anti-PGL-1 in both groups 
1 and 2 before the beginning of the MDT regimens (6.95 ± 
1.35 and 12.53 ± 2.02, respectively) and lower levels after 
the end of MDT regimens (2.78 ± 0.69 and 2.62 ± 0.79, 
respectively). In both groups, the difference between these 
values was statistically significant (P < 0.01), indicating that 
the short-term MDT regimen led to a reasonable improve-
ment of leprosy patients. In group 3, we found lower levels 
of anti-PGL-1, which were maintained before and after 
MDT therapy for 6 months (1.28 ± 0.35 and 0.62 ± 0.12; 
respectively, Table 1), as expected for PB patients. 
The BI was also sequentially evaluated. PB patients 
obviously had a negative BI, whereas MB patients had posi-
tive bacillary smears. In groups 1 and 2, we found higher BI 
levels before the beginning of the MDT regimens (1.26 and 
1.66, respectively) and lower levels after the end of MDT 
regimens (0.26 and 0.36, respectively). The differences 
between these values before and after the MDT regimens 
were statistically significant in both groups (P < 0.01). 
Antibody levels were correlated to the BI. The correlation 
coefficient (Pearson’s r) was 0.72 before and 0.23 (P < 0.05) 
after treatment in group 1 and 0.67 before and 0.96 (P < 
0.05) after treatment in group 2. Since MB patients treated 
for 12 months with MDT-MB exhibited a large number of 
negative BI (BI = 0), we found a lower value of Pearson’s 
r in these patients (0.23).
Discussion
Since the region of Ribeirão Preto (SP, Brazil) is known 
to be an area of difficult control of leprosy due to the high 
migration from different regions, controlled studies to evalu-
ate patients under both short- and long-term chemotherapy 
are important requirements for the elimination of leprosy 
as a public health problem. 
An important factor predisposing to relapse is inad-
equate or irregular therapy, since the duration of the clas-
sical treatment regimen (24 months) is very long. A shorter 
treatment regimen (12 months) may improve the adherence 
of the patients to treatment. Thus, our study compared the 
outcomes of treatment with 12-month vs 24-month MDT 
regimens in leprosy patients.
Previous studies comparing the two regimens of leprosy 
treatment were based on clinical outcomes and BI variations 
during the course of treatment and after discharge (15). 
Since serology could provide a method to monitor leprosy 
patients under treatment (1), in the present study the out-
come of leprosy treatment was studied not only on the basis 
of BI, but also on the basis of anti-PGL-1 levels. 
Serology is a marker of a higher systemic bacterial 
load and may identify potential infectious sources among 
patients with few clinical signs. It is accepted that there is a 
correlation between BI and anti-PGL-1 levels, which could 
be applied as a serum marker of the patient’s bacterial load, 
presenting high sensitivity and specificity when used for MB 
leprosy patients (4,6). Our results support this statement, 
since a significant correlation between anti-PGL-1 levels 
and bacterial load, measured by the BI, was noted. We 
observed lower levels of anti-PGL-1 and BI in PB patients 
independently of treatment. Results from previous PGL-1 
studies have demonstrated that the technique is sensitive 
for MB leprosy but detects only 30 to 60% of PB cases 
(4,6). On the other hand, we noted higher levels of anti-
PGL-1 and BI in MB patients before the beginning of MDT 
and a decrease in BI and anti-PGL-1 levels after the end of 
treatment, both for the short-term (12 month) and long-term 
(24 month) regimens.
The seronegative conversion of anti-PGL-1 antibodies 
is considered useful for monitoring the clearance of the 
bacterial load, thus measuring the effect of MDT (4,6,20). 
The present data showed a statistically significant differ-
ence in anti-PGL-1 levels determined in MB patients before 
treatment and after 12 and 24 months of MDT, suggesting 
that both short-term and long-term MDT regimens led to a 
reasonable improvement of leprosy patients, in agreement 
Table 1. Anti-PGL-1 levels of patients with leprosy before and after treatment. 
Group Time Mean ± SEM SD CV Min Q1 Median Q3 Max P
MDT-MB-12 months (N = 34)
Before 6.95 ± 1.35 7.85 112.97 0.20 1.10 3.20 9.60 28.0 <0.01
After 2.78 ± 0.69 3.98 143.16 0.00 0.60 1.00 2.20 14.0
MDT-MB-24 months (N = 33)
Before 12.53 ± 2.02 11.60 92.61 0.60 3.90 8.80 24.20 40.0 <0.01
After 2.62 ± 0.79 4.54 173.48 0.20 0.60 1.50 2.00 20.0
MDT-PB-6 months (N = 38)
Before 1.28 ± 0.35 2.17 169.92 0.00 0.40 0.70 1.40 13.5
After 0.62 ± 0.12 0.74 119.53 0.00 0.30 0.50 0.70 4.5
Groups: MDT-MB-12 months = multibacillary patients treated for 12 months with multidrug therapy; MDT-MB-24 months = multibacil-
lary patients treated for 24 months with MDT; MDT-PB-6 months = paucibacillary patients treated for 6 months with MDT. CV = coef-
ficient of variation; Min = minimum value; Q1 = 1st quadrant; Q3 = 3rd quadrant; Max = maximum value. P < 0.01 comparing values 
before and after treatment (mixed linear model).
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with a preliminary study (15). This may reflect clearance of 
large numbers of bacilli in patients early during treatment 
(before 12 months), since there is a significant correlation 
between anti-PGL-1 levels and bacterial load. The tendency 
of low anti-PGL-1 levels to remain positive may be related 
to bacillary persistence, a known phenomenon of leprosy. 
It has been repeatedly shown that macrophages in MB 
leprosy patients are not able to clear M. leprae efficiently 
from lesions because dead organisms and their fragments 
continue to persist even after the end of treatment (21). 
Furthermore, in lepromatous patients under therapy, the 
duration of treatment seems to be a very important factor 
for the development of anti-PGL-1 levels, since patients 
treated for as long as 18 months had positive anti-PGL-1 
levels, whereas patients treated for a long time (5 years or 
more) had normal antibody levels (11). A serologic test for 
the diagnosis of subclinical infection and for therapeutic 
follow-up has been applied, despite the high specificity 
and controversies surrounding the correlation of high lev-
els of anti-PGL-1 antibodies with active, previous or future 
disease (11,12).
Taken together, the results obtained here using sero-
logical testing indicate that the determination of anti-PGL-1 
levels not only is a suitable method for the detection of 
leprosy activity, but is also a rapid, sensitive and inexpen-
sive tool for the evaluation of treatment efficacy (1,3). We 
conclude that sequential serum measurements are helpful 
to understand the dynamics of antibody production during 
the course of leprosy. Our study permitted us to determine 
a clear antibody profile directly associated with the BI. 
Follow-up studies of MB patients treated for 12 and 24 
months with MDT indicated that the majority of patients 
tested negative for M. leprae both in skin washings and nasal 
secretions as determined by direct microscopic observation 
and PCR. The same patients remained BI positive when 
analyzed by routine slit-skin smears and biopsy after 1 year 
of MDT (21). Since the present study showed seronega-
tive conversion of anti-PGL-1 antibodies in MB patients 
treated with MDT for both 12 and 24 months, it is possible 
that the control of leprosy infection can be obtained with 12 
months of MDT in MB patients, relieving patients of long 
treatment periods. Thus, the adherence of the patients to 
the treatment should improve, leading to the elimination of 
viable M. leprae rapidly and blocking the transmission of 
the infection. Based on these observations, a reduction in 
length of chemotherapy may facilitate patient compliance 
and national health program activities.
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